Patents by Inventor Gilles Galvani

Gilles Galvani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230285381
    Abstract: The present invention relates to compounds of formula (I); for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: April 6, 2023
    Publication date: September 14, 2023
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS-SACLAY, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
  • Publication number: 20220280498
    Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: May 26, 2022
    Publication date: September 8, 2022
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SUD, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
  • Patent number: 11376245
    Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: July 5, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SUD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia Cohen-Kaminsky, Marc Humbert, Sebastien Dumas, Gilles Bru-Mercier, Samir Messaoudi, Jean-Daniel Brion, Mouad Alami, Gilles Galvani
  • Patent number: 11247982
    Abstract: The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of 1-(indol-3-yl)-3-hydroxy-3-(2-oxo-2-ethyl)-indol-2-ones type, as a drug, and the use of such compounds in the preparation of pharmaceutical compositions. These pharmaceutical compositions may in particular be intended to prevent or treat diseases involving NMDA receptors of the central nervous system, in particular severe/resistant epilepsy and cognitive disorders resulting therefrom, especially autism, but also strokes, schizophrenia, degenerative diseases involving the activation of NMDA receptors, such as Parkinson's disease and Alzheimer's disease, Rett syndrome, or amyotrophic lateral sclerosis, migraine, dementia and major depressive disorder.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: February 15, 2022
    Assignee: ADPUERIVITAM
    Inventors: Mouad Alami, Jean Daniel Brion, Samir Messaoudi, Sabrina Touchet, Gilles Galvani, Olivier Dulac, Svetlana Gataullina, Caroline Nous
  • Publication number: 20200385363
    Abstract: The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of indole-1-yl-(1H)-quinoline-2-one and indole-3-yl-(1H)-quinoline-2-one type, as a drug, and the use of such compounds in the preparation of pharmaceutical compositions. These pharmaceutical compositions may in particular be intended to prevent or treat diseases involving NMDA receptors of the central nervous system, in particular severe/resistant epilepsy and cognitive disorders resulting therefrom, especially autism, but also strokes, schizophrenia, degenerative diseases involving the activation of NMDA receptors, such as Parkinson's disease and Alzheimer's disease, Rett syndrome, or amyotrophic lateral sclerosis, migraine, dementia and major depressive disorder.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 10, 2020
    Inventors: Mouad Alami, Jean Daniel Brion, Samir Messaoudi, Sabrina Touchet, Gilles Galvani, Olivier Dulac, Svetlana Gataullina, Caroline Nous
  • Patent number: 10538482
    Abstract: The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: January 21, 2020
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud
    Inventors: Marc Humbert, Sylvia Cohen-Kaminsky, Sébastien Dumas, Gilles Bru-Mercier, Mouad Alami, Jean-Daniel Brion, Samir Messaoudi, Gilles Galvani
  • Publication number: 20190307738
    Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: June 13, 2017
    Publication date: October 10, 2019
    Applicants: Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS), Universite Paris SUD, Assistance Publique-Hopitaux de Paris (APHP), Hopital Marie Lannelongue
    Inventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
  • Publication number: 20180215699
    Abstract: The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: July 26, 2016
    Publication date: August 2, 2018
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique-Hôpitaux De Paris, Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud
    Inventors: Marc Humbert, Sylvia Cohen-Kaminsky, Sébastien Dumas, Gilles Bru-Mercier, Mouad Alami, Jean-Daniel Brion, Samir Messaoudi, Gilles Galvani